Cell‐of‐origin in diffuse large B‐cell lymphoma: findings from the UK's population‐based Haematological Malignancy Research Network

Cell‐of‐origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B‐cell lymphoma

“…The UC cases in our study had an outcome comparable to patients classified as GCB. This is in contrast to other studies showing that the UC cases are more likely to be grouped together with the ABC subtype with an inferior patient outcome, although others have shown results similar to ours . The UC patients in our cohort did not differ significantly from GCB patients regarding clinical characteristics.…”

The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK’s population-based Haematological Malignancy Research Network

“…This report includes 6834 patients newly diagnosed 01/2009-07/2015 with one of the five commonest mature B-cell malignancies, DLBCL (n = 1771), MM (n = 1760), CLL (n = 1580), MZL (n = 936), or FL (n = 787), and their age- and sex-matched counterparts from the general population cohort (n = 68,340). In addition to examining core diagnostic/prognostic clinical data, for DLBCL patients with available data/material we examined cell-of-origin assigned on the basis of: 1) immunohistochemical expression of CD10, BCL6 and IRF4/MUM1 [ 24 ]; and 2) gene-expression profiling of pre-treatment biopsies analysed using the Illumina WG-DASL and DLBCL automatic classifier (DAC) [ 13 , 25 , 26 ].…”

“…Among the strongest and most consistently reported associations are those between B-cell lymphomas – particularly diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL) – and chronic B-cell-activating inflammatory diseases notably rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s syndrome [ [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] ]. Furthermore, there is some evidence to suggest that DLBCL patients with chronic inflammatory conditions are more likely to be diagnosed with the activated B-cell (ABC) subtype [ 5 , 12 ], which has a poorer prognosis than the germinal centre B-cell (GCB) subtype and tends to be diagnosed at a slightly older age [ 13 , 14 ].…”

Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit

“…Of the 697 DLBCL cases included, 400 were from the REMoDL-B trial (28 MYC translocation positive) and 297 (97 MYC translocation positive) from a UK populationbased cohort [25,28]. The vast majority of cases in the population-based cohort were from the Haematological Malignancy Research Network (HMRN) (www.hmrn.org), which tracks all haematological malignancies across 14 hospitals diagnosed by a centralised fully-integrated haematopathology laboratory [29].…”

“…Among these recent advances, Sha et al and Ennishi et al have defined a clinically and biologically distinct high-risk subgroup within GCB-DLBCL using, respectively, a Burkitt lymphoma-like or MYC/BCL2-DHfounded gene expression signature [25][26][27]. This subgroup, termed molecular high-grade (MHG) in the study by Sha et al, is enriched in cases with MYC/BCL2-DH, and more importantly includes other poor prognosis cases without the double-hit, which are not readily identified by other methods [25,28].…”